GPI formed part of the extensive lineup of speakers, presentations and workshops at the HTAi Virtual Conference, that took place from June 19 – 23. Early Pricing & Market Access Forecasting for Orphan Assets Our research into “Early Pricing and Market Access Forecasting for…
GPI Consulting performed net price forecasting and launch optimisation for an IO asset upon UK oncology indication expansion for top tier pharmaceutical. GPI’s consulting team leverage our data and analytics platform pulse™ and HORIZON methodology to assist a number of our clients analyse…
Date: 19 – 23 June 2021 | Virtual GPI are forming part of the extensive lineup of speakers, presentations and workshops at the HTAi Conference, taking place virtually from June 19 – 23. Early Pricing & Market Access Forecasting for Orphan Assets Our…
London, UK / Berlin, Germany. June 2nd, 2021 – Global Pricing Innovations, leading provider of pharma pricing insights, has joined Datarade, the fastest-growing data marketplace. Datarade’s tens of thousands of data buyers from every industry can now effortlessly discover, compare, and get access…
Tuesday, June 29 | 7am PDT // 3pm BST An Innovative Approach to Managing Pricing and Launch Strategies How you price your drugs is a big and important decision. But if you’re like most pharmaceutical companies, you don’t have a comprehensive system that…
A blog conducted by CBI Insights (Killing Strategy: the disruption of management consulting) highlights the disruption of management consulting and how companies are responding, aiming for the perfect consultant/client relationship. The blog describes how technological innovation has driven change in the management consulting…
Sam Fieldwick joins GPI, as part of the Commercial Development team GPI are pleased to announce and welcome Sam Fieldwick as the new Commercial Development Manager. Sam will be responsible for working with existing and new clients, driving revenue for GPI and the…
Leveraging a Value-Driven Approach to Price Forecasting GPI’s Eva Barkhauskaite, Rachel Jao, Preeti Patel and Tom Brockbank look at early pricing and market access forecasting for orphan assets. The research takes an analytical approach to asset price forecasting, and price value optimisation, designed…
GPI Consulting supported a multinational biopharmaceutical company in forecasting their early-stage assets’ commercial opportunities. GPI’s consulting team leverage our data and analytics platform pulse™ and HORIZON methodology to assist a number of our customers analyse and define their market access strategy. In this…
This month’s employee spotlight shines a light on one of our new starters, Sevcan Cigerli. At GPI, people are at the heart of our success and we want you get to know our staff better. This month, we focus on one of our…
GPI ScrumMaster Stephen Jeffries describes how GPI’s agile approach aids teamworking, collaboration and project excellence. Joining a new organisation is always a challenging time. Understanding the company culture, learning new systems, technology and quickly coming up to speed with fast-moving projects. GPI is…
Change is Good GPI drive effective and efficient access to medicines with faster insights and sustainable pricingstrategies. We love what we do and our work is always reflective of our core values: authenticity, sustainability, quality matters, and change is good. At GPI, we…
London, UK., April 28, 2021 – Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced a strategic life sciences industry partnership with Global Pricing Innovations (GPI), a market leader in analytics, insights and innovative solutions that help life…
London, UK., April 28, 2021 – Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced a strategic life sciences industry partnership with Global Pricing Innovations (GPI), a market leader in analytics, insights and innovative solutions that help life…
The news comes as during the COVID-19 pandemic, women have lost their jobs or left the labour force in greater numbers than men. JP Morgan have a long standing commitment to supporting and promoting female-powered businesses, and this report highlights the changes we…
GPI Consulting supported one of the largest players in the plasma-derived space in developing price and product allocation strategy for 2021 across key commercial markets. GPI’s consulting team leverage our data and analytics platform pulse™ and HORIZON methodology to assist a number of…
This month’s employee spotlight shines a light on our Founder and CEO, Preeti Patel. At GPI, people are at the heart of our success and we want you get to know our staff better. This month, we focus on our Founder and CEO,…
Thursday 15th April, 2021 – Global Pricing Innovations (GPI), announce innovative solution to empower insightful decision-making for the BioPharma industry. GPI pulse™ 2.0 launches, providing a more intuitive and powerful analytics platform. The pace of drug development is rapidly accelerating with the rise…
At GPI, our work is centred around our FOUR core values: Quality Matters, Sustainability, Authenticity and Change is Good. Every day, our amazing staff go above and beyond for our customers and strive to maintain the high quality standards and values that GPI…
GPI leverages HORIZON methodology to support mid-sized bio-pharma company to optimise multi-indication launch sequence. GPI’s HORIZON methodology has helped a number of our customers to analyse and define market access strategy. In this instance, GPI was able to use HORIZON methodology to support…
The French state-industry drug framework agreement stipulates that innovative products manufactured in the country can have the same initial price as the highest one applied in Germany, the UK, Italy, or Spain. The new 2021-24 framework agreement signed on Friday 5th March between…
GPI pulse™ is a dynamic value, price, and access analytics platform, utilising powerful algorithms to combine multiple data streams in a way that will give you unique insight into the full market access journey. The platform is designed to be used as part…
By Musa Kureshy, MSc, Business Development Manager, Global Pricing Innovations Opportunity Assessments are a vital step for in-licensing new pipeline products or making go/no-go decisions around the clinical development of early-stage assets. To be able to achieve a reliable opportunity assessment it requires…
Recently Spain’s medicines regulatory bodies announced the requirement of additional “economic evaluation” data for therapeutics positioning reports (IPTs) which is the equivalent of a Health Technology Assessment process in the country. This change is part of a revolution of the overall HTA process…
By Rangaraja Konar, MBA, Business Analyst, Global Pricing Innovations Joseph Biden has been elected as the 46th President of the United States of America. He was the vice president of the states during Obama’s administration. The healthcare sector might be up to face…
PFIZER AND BIONTECH HAVE PRODUCED BETTER THAN EXPECTED EFFICACY RESULTS BUT WILL AWAIT FOR SAFETY DATA BEFORE FILING LATER THIS MONTH. THE PHIII INTERIM ANALYSIS FINDS VACCINE 90% EFFECTIVE WITH EUA FILING EXPECTED LATE NOVEMBER. Pfizer and BioNTech have announced positive interim Phase…
Blogpost by Dimitra Sotou, MIHP, Client Solutions Lead, GPI Canada is due to adjust its international reference pricing (#IRP) basket of comparator countries come January, the 1st, 2021. The change was announced by the PMPRB in the final version of new guidelines; after five years…
Blogpost created by Dimitra S. Sotou, Client Solutions Lead, Pricing & Market Access As opposed to the rest of key EU payers focusing on cost containment strategies for 2021, the German umbrella payer group GKV-Spitzenverband (GKV-SV) has announced to be targeting a +4.6%…
The White House has blocked stricter Food and Drug Administration (FDA) guidelines for the emergency release of the coronavirus vaccine, that would have likely prevented its approval before next month’s presidential election. The new FDA guidelines were submitted for approval to the Office…
Spending Changes Recently the French government has published its Social Security Finance Bill 2021 (PLFSS 2021), which covers the annual review of their health and social security expenditure. With the impact of COVID-19 increasing there seems to be an ever-increasing cost cutting exercise…
By Dimitra S. Sotou, Senior Consultant It’s been quite long since the US administration has been contemplating on techniques and mechanisms to lower prescription medicine prices covered by #Medicare . Different ideas have been brought onto the table over the past year with…
By Musa Kureshy, Business Development Manager The impact of COVID-19 has been felt by every country and industry and the Netherlands was no exception. COVID-19 impactied drug manufacturing in China leading to it coming to a stand still and India implemented export restrictions…
News summarised by Dimitra S. Sotou, Sr. Consultant, Pricing & Market Access ”Sputnik V” On Tuesday, President Vladimir Putin, announced that Russia is the first nation in the world to grant approval to a coronavirus vaccine. The approval has been granted, despite the…
Find out how the notion of value based pricing methodologies are becoming more common place in pharmaceutical medicines pricing and how Indication-based pricing (IBP) has been proposed as a potential solution for any medicine that offers benefits across many different indications. In this…
By Dimitra Sotou, Senior Consultant The Background The Italian Government has recently introduced new pricing and reimbursement rules with the central aim of making therapeutic value of prime importance in the assessment of new medicinal products conducted by AIFA. News sources confirm that…
By Tom Brockbank, Senior Consultant, Pricing & Market Access Trump announced on Friday 24th July, a one-month ultimatum for drug manufacturers to offer alternative plans to reduce drug prices. This will provide manufacturers an alternative option to the stalled plan to reference drug…
By Tom Brockbank, Senior Consultant, Pricing & Market Access Germany’s major payer AOK announces discount agreements and drug manufacturer incentives to ensure a stable supply chain throughout the COVID-19 pandemic AOK has announced two-year discount agreements for 119 drugs and an obligation for…
At GPI, working daily with price and reimbursement data, we have seen a range of PMA trends across high unmet need areas such as orphan/rare diseases. Increasing pharma focus on rare diseases resulted in payers having to adapt their strategies of recent, often…
By Musa Kureshy, Business Development Manager & Tom Brockbank, Senior Consultant On Tuesday 16th of June, new research was published by scientists from Oxford University which showed that the use of Dexamethasone, a low-dose steroid treatment, on patients suffering from COVID-19 reduced deaths…
By Ines Dieringer, Associate Consultant at Global Pricing Innovations Belgium, the Netherlands, and Ireland are aiming to undertake a joint Health Technology Assessment (HTA) through the Beneluxa agreement of Zolgensma, Novartis’ gene therapy medication to treat spinal muscular atrophy (SMA)1. Zolgensma is a…
AUTHORS: Barkauskaite E, Patel P Beginning of the week and Day 1 for ISPOR Virtual 2020 today – We are very excited to share more results from our extensive R&D work. The infographic below provides a summary of the results of an indication…
AUTHORS: Sotou D, Barkauskaite E, Patel P Despite the worldwide impact due to COVID-19 pandemic, GPI continues to invest on extensive R&D work leading the way on how data can be leveraged to ensure our partners stay ahead of the curve. We are…
By Nairuti Patel, Associate Consultant, Global Pricing Innovations Amidst the COVID-19 pandemic, EU countries (Estonia, Greece, Netherlands and Romania) requested an opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the conditions under which early access to remdesivir through compassionate…
By Ines Dieringer, Associate Consultant The COVID-19 crisis has altered the way in which vaccines and drugs are developed and approved. In the private sector, we see unprecedented partnerships arise, while the public sector has experienced a policy shift towards a system of…
By Dimitra Sotou, Senior Consultant, Pricing & Market Access Day 1 of official lockdown today, and increasingly more organizations around the globe are facing tighter operational restrictions due to the COVID-19 outbreak – Name it: day-to-day work, restricted travel, team meetings, cancelled conferences,…
We hope you are all safe and in good health. At GPI, we are extremely proud to present our new offering, GPI HORIZON, an innovative methodology supporting early price and access forecasting. Despite the uncertainty and change brought by COVID-19 outbreak, GPI have…
Pricing & Market Access leader enhances pricing database with world’s leading analytics platform for technology developers London, UK, March 17, 2020 – Global Pricing Innovations (GPI), a leader in analytical market access solutions for biopharma, has announced the Spring 2020 release of new features…
Author – Nairuti Patel (Associate Consultant, GPI) On 3rd March 2020, the Spanish Council of Ministers announced a ‘specific pricing system’ for orphan medicinal product that will be separate from the reference pricing system. The reference pricing system applies to all other products reimbursed by the Spanish National Health System (SNS) when their patent has expired. The only instance when orphan drugs will be included in this new…
At the end of 2019, important legislative changes took place in the United States that could impact the country’s pharmaceutical industry over the coming years. The U.S. House of Representatives has passed the Lower Drug Costs Now Act on 12th December 2019, setting…
By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…
